Back to Search
Start Over
Short report: lack of prediction of amodiaquine efficacy in treating Plasmodium falciparum malaria by in vitro tests.
- Source :
-
The American journal of tropical medicine and hygiene [Am J Trop Med Hyg] 2004 Sep; Vol. 71 (3), pp. 294-6. - Publication Year :
- 2004
-
Abstract
- Amodiaquine (AQ) is currently a major candidate for new antimalarial combinations, although in vivo and in vitro tests have been rarely simultaneously investigated. The efficacy of AQ was assessed at the dose of 30 mg/kg in treating Plasmodium falciparum malaria attacks in 74 children from southeast Gabon, and the in vitro activity of monodesethylamodiaquine (MdAQ), the main metabolite of AQ, was measured against P. falciparum parasites isolated from these children. Treatment failures were observed in 40.5% of the children, while 5.4% of the isolates showed in vitro resistance to MdAQ. No relationship was observed between in vivo and in vitro susceptibility. The in vitro activities of MdAQ and chloroquine were correlated. The reasons for such disparities between in vivo and in vitro AQ activities are discussed and the issue of the validity of in vitro tests to measure AQ efficacy is raised.
- Subjects :
- Amodiaquine metabolism
Child
Child, Preschool
Drug Resistance genetics
Gabon
Humans
In Vitro Techniques
Malaria, Falciparum genetics
Parasitic Sensitivity Tests methods
Predictive Value of Tests
Treatment Outcome
Amodiaquine analogs & derivatives
Amodiaquine therapeutic use
Antimalarials therapeutic use
Malaria, Falciparum drug therapy
Subjects
Details
- Language :
- English
- ISSN :
- 0002-9637
- Volume :
- 71
- Issue :
- 3
- Database :
- MEDLINE
- Journal :
- The American journal of tropical medicine and hygiene
- Publication Type :
- Academic Journal
- Accession number :
- 15381809